This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (37)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Depletion of vaginal lactobacilli has been associated with increased risk of urogenital infections including bacterial vaginosis (BV) and acquisition of human immunodeficiency virus (HIV).¹ We conducted a randomized controlled trial to compare combination therapy with probiotic Lactobacillus rhamnosus GR-1 and L fermentum RC-14 vs commercially available Lactobacillus rhamnosus GG in colonizing the vagina following menstruation. The GG strain, however, may not be an optimal choice to prevent urogenital infections, as it has been shown to be ineffective in preventing urinary tract infections.² Furthermore, unlike RC-14, GG does not express any anti-infective proteins against urogenital pathogens.³ We therefore also sought to determine whether GR-1 and RC-14 have antiyeast and antiviral properties.

Methods

Subjects were 29 healthy, white, premenopausal, nonpregnant women, who were without signs or symptoms of urogenital infection. Subjects were excluded if they were using antibiotics, spermicides, or immunosuppressive agents at the start of the study. Subjects were . . . [Full Text of this Article]

RELATED ARTICLE

Data Withholding in Academic Genetics: Evidence From a National Survey
Eric G. Campbell, Brian R. Clarridge, Manjusha Gokhale, Lauren Birenbaum, Stephen Hilgartner, Neil A. Holtzman, and David Blumenthal
JAMA. 2002;287(4):473-480.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of Reuterin Production in Urogenital Probiotic Lactobacillus reuteri RC-14
Cadieux et al.
Appl. Environ. Microbiol. 2008;74:4645-4649.
ABSTRACT | FULL TEXT  

Probiotics in health maintenance: do they really work?
Balcazar
British Journal of Infection Control 2007;8:26-29.
ABSTRACT  

Probiotics: Not Just for Treatment Anymore
Van Niel
Pediatrics 2005;115:174-177.
FULL TEXT  

In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp.
Goldstein et al.
Antimicrob. Agents Chemother. 2004;48:2149-2152.
ABSTRACT | FULL TEXT  

Potential Uses of Probiotics in Clinical Practice
Reid et al.
Clin. Microbiol. Rev. 2003;16:658-672.
ABSTRACT | FULL TEXT  

In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria
Goldstein et al.
Antimicrob. Agents Chemother. 2003;47:1968-1971.
ABSTRACT | FULL TEXT